APPY talk: is Venaxis's appendicitis test finally set for approval?
This article was originally published in Clinica
Executive Summary
After many setbacks, Venaxis is hopeful that its APPY1 appendicitis test could soon be cleared by the US FDA. The company has just reported what it says are positive top-line results from its pivotal trial: it found a negative predictive value (NPV) of 97%, sensitivity of 97% and specificity of 38%.